Torrent Pharmaceuticals is gearing up to release both oral and injectable versions of Semaglutide, a popular diabetes and weight loss drug, after the patent expires in early 2026. The company plans to produce the active pharmaceutical ingredient (API) in-house at its manufacturing plant in Gujarat’s Dahej while potentially outsourcing some parts of the formulation process to optimize production costs and timelines. This move comes as generic drugmakers, including Torrent, are eyeing opportunities in the market following Novo Nordisk’s current monopoly over the molecule in India. Semaglutide, a GLP-1 receptor agonist found in brands like Ozempic and Wegovy, has gained worldwide popularity for its effectiveness in managing type 2 diabetes and obesity. With Novo Nordisk facing supply constraints, Torrent’s entry into the market could help meet the growing demand for GLP-1 drugs in India’s diabetes and obesity segment. As the Indian market for Semaglutide is expected to expand post-patent expiry, other major pharmaceutical companies like Dr. Reddy’s Laboratories, Cipla, and Biocon are also gearing up for their own launches in the GLP-1 space. Stay tuned for more updates on this evolving pharmaceutical landscape.
Read more from medicaldialogues.in